Miliary tuberculosis after infliximab therapy in Lebanon.
Uthman
Imad
I
Kanj
Nadim
N
El-Sayad
Jinane
J
Bizri
Abdul-Rahman
AR
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D007861:Lebanon; D008297:Male; D009169:Mycobacterium tuberculosis; D011241:Prednisone / Q000627:therapeutic use; D017511:Pyoderma Gangrenosum / Q000188:drug therapy; D014391:Tuberculosis, Miliary / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology
D000911:Antibodies, Monoclonal; D000995:Antitubercular Agents; D003879:Dermatologic Agents; D005938:Glucocorticoids; D000069285:Infliximab; D011241:Prednisone